ZURAGARD
Peakisopropyl alcohol
NDATOPICALSOLUTION
Approved
Apr 2019
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
ZURAGARD (isopropyl alcohol) is 2 (d 2 ) and serotonin type 2 (5ht 2 ) antagonism. First approved in 2019.
Drug data last refreshed 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZURAGARD is an isopropyl alcohol topical solution approved in 2019 for the treatment of eye irritation. The mechanism of action involves dopamine type 2 (D2) and serotonin type 2 (5HT2) antagonism, delivered via topical application. This product addresses acute ocular irritation in patients seeking symptomatic relief.
Peak10.0 years to LOE
Peak lifecycle stage with 9 linked positions indicates stable commercial operations; manufacturing-heavy team structure suggests focus on operational excellence and cost optimization.
Mechanism of Action
2 (D 2 ) and serotonin type 2 (5HT 2 ) antagonism.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ZURAGARD positions offer career opportunities primarily in manufacturing operations and process optimization, reflecting a mature product in peak lifecycle requiring operational excellence and cost control. The manufacturing-heavy job portfolio suggests roles focused on supply chain reliability, quality assurance, and production scaling rather than commercial expansion.
Manufacturing AssociateManufacturing Technician
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.